Aurigene Announces First in Human Dosing with RoRyt Inverse Ag...
BOSTON, July 12, 2018 /PRNewswire-AsiaNet/ -- - Phase 1 data from the study expected to be available by December 2018Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders, announced today that it has commenced dosing ...